# Abingdon Health Reports 30% Revenue Growth for FY26 and Reaches H2 Profitability

- URL: https://stocks.freetheai.org/news/abingdon-health-reports-30-revenue-growth-for-fy26-and-reaches-h2-profitability-dcd285
- Published: 2026-10-13T06:00:03Z
- Category: earnings; sentiment: mixed; impact: medium
- Symbols: [LSE:ABDX](https://stocks.freetheai.org/symbols/LSE-ABDX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Abingdon Health plc (ABDX) reported full-year results for the period ended 30 June 2026, delivering reported revenue of £11.0 million, up 30% from £8.4 million in the previous year. Total revenue including grant funding reached £11.3 million. Growth was led by a 56% surge in contract development revenue to £5.0 million.

The expansion drove stronger operational performance in the second half of the year, with H2 revenue rising 62% over H1. Abingdon Health achieved positive adjusted EBITDA trading in H2, narrowing its full-year adjusted EBITDA loss to £1.5 million from £2.6 million. Full-year pretax loss reduced to £2.0 million from £3.5 million, while gross margin expanded to 47.1%. Cash balances increased to £2.9 million by year-end, supported by a £3.2 million net equity raise in October 2025.

Looking ahead to FY27, management expects revenue to be heavily weighted toward the second half due to first-quarter project delays linked to reagent availability and specification updates. However, the group anticipates continued revenue growth and a further improvement in its full-year EBITDA position, supported by expanding capabilities at its US manufacturing site in Madison.

## Key points

- Reported revenue for FY26 rose 30% to £11.0 million, supported by a 56% increase in contract development income to £5.0 million.
- Abingdon Health achieved adjusted EBITDA profitability in H2 FY26, reducing its full-year adjusted EBITDA loss to £1.5 million.
- Loss before tax narrowed to £2.0 million from £3.5 million in FY25, while gross margin expanded to 47.1%.
- Cash and cash equivalents grew to £2.9 million at year-end, boosted by a £3.2 million net equity fundraising.
- Management expects FY27 revenue to be second-half weighted due to short-term Q1 delays, with overall annual EBITDA improving over FY26.

## Questions and answers

### What were Abingdon Health's financial results for FY26?

Abingdon Health reported £11.0 million in revenue for FY26, a 30% increase year over year. Pretax loss narrowed to £2.0 million, and the company achieved positive adjusted EBITDA trading in the second half of the year.

### Why does Abingdon Health expect FY27 revenue to be second-half weighted?

First-quarter revenue activities faced short-term delays due to raw material reagent availability and project specification changes, pushing more revenue generation into the second half of FY27.

### What is Abingdon Health's cash position?

Abingdon Health ended FY26 with £2.9 million in cash and cash equivalents, up from £1.9 million at the end of FY25, supported by a £3.2 million net equity fundraise completed in October 2025.